About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« A Step-by-Step Approach to Patent Subject Matter Eligibility Reform | Main | CVC Files Motion in Opposition to Broad's Substantive Motion No. 4 »

February 18, 2020

Comments

"[O]ther biologic drugs will (eventually) exhaust the 12 years of market exclusivity... [T]he pace of biosimilar approval is increasing and this trend can be expected to continue."

I think that this is the really important part. If we have not yet gotten as many generic biologics approved as the BPCIA's boosters had hoped, it is because it takes time for these things to clear their data exclusivity periods. Each day brings us closer to such periods ending, and a corresponding increase in the incidence of biologic generics.

The comments to this entry are closed.

July 2020

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31